Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues

Histopathology

Volumn 54, Issue 5, 2009, Pages 598-606

  Martinez, Juan Carlos ^a   Müller, Marcus M ^a   Turley, Helen ^a   Steers, Graham ^a   Choteau, Ludovine ^a   Li, Ji Liang ^b   Sainson, Richard ^b   Harris, Adrian L ^b   Pezzella, Francesco ^a   Gatter, Kevin C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Delta like ligand 4; Human tissues; Nuclear relocation

Indexed keywords

DELTA LIKE LIGAND 4; GROWTH FACTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL MEMBRANE; CELL NUCLEUS; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CYTOPLASM; ENDOTHELIUM; EPITHELIUM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG ALVEOLUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROSCOPY, CONFOCAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TISSUE ARRAY ANALYSIS; TRANSFECTION;

MAMMALIA;

EID: 64549114965     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03279.x     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 57 70.
2. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 2335 2342.
3. Laskin JJ, Sandler AB. First-line treatment for advanced non-small-cell lung cancer. Oncology 2005 19 1671 1676 discussion 8-80.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005 438 967 974.
5. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 2006 3 24 40.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 8 299 309.
7. Kerbel RS, Yu J, Tran J et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001 20 79 86.
8. Radtke F, Schweisguth F, Pear W. The Notch 'gospel'. EMBO Rep. 2005 6 1120 1125.
9. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat. Rev. Mol. Cell Biol. 2002 3 673 684.
10. Lobov IB, Renard RA, Papadopoulos N et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl Acad. Sci. USA 2007 104 3219 3224.
11. Hellstrom M, Phng LK, Hofmann JJ et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007 445 776 780.
12. Suchting S, Freitas C, le Noble F et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl. Acad. Sci. USA 2007 104 3225 3230.
13. Noguera-Troise I, Daly C, Papadopoulos NJ et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 2006 444 1032 1037.
14. Ridgway J, Zhang G, Wu Y et al. Inhibition of Dll4 signalling inhibits tumor growth by deregulating angiogenesis. Nature 2006 444 1083 1087.
15. Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 2007 445 781 784.
16. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 2007 134 839 844.
17. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006 107 931 939.
18. Li JL, Sainson RC, Shi W et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007 67 11244 11253.
19. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl Acad. Sci. USA 1979 76 4350 4354.
20. Burnette WN. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 1981 112 195 203.
21. Poulsom R, Longcroft JM, Jeffery RE, Rogers LA, Steel JH. A robust method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine pathology specimens. Eur. J. Histochem. 1998 42 121 132.
22. Ponte P, Gunning P, Blau H, Kedes L. Human actin genes are single copy for alpha-skeletal and alpha-cardiac actin but multicopy for beta- and gamma-cytoskeletal genes: 3′ untranslated regions are isotype specific but are conserved in evolution. Mol. Cell. Biol. 1983 3 1783 1791.
23. Gale NW, Dominguez MG, Noguera I et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl Acad. Sci. USA 2004 101 15949 15954.
24. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996 380 439 442.
25. Benedito R, Duarte A. Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. Gene Expr. Patterns 2005 5 750 755.
26. Fung E, Tang SM, Canner JP et al. Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation 2007 115 2948 2956.
27. Schaller MA, Neupane R, Rudd BD et al. Notch ligand Delta-like 4 regulates disease pathogenesis during respiratory viral infections by modulating Th2 cytokines. J. Exp. Med. 2007 204 2925 2934.
28. Mazella J, Liang S, Tseng L. Expression of Delta-like protein 4 in the human endometrium. Endocrinology 2008 149 15 19.
29. Ilagan MX, Kopan R. SnapShot: notch signaling pathway. Cell 2007 128 1246.
30. Pelkmans L, Fava E, Grabner H et al. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 2005 436 78 86.
31. Polo S, Di Fiore PP. Endocytosis conducts the cell signaling orchestra. Cell 2006 124 897 900.
32. Le Borgne R, Bardin A, Schweisguth F. The roles of receptor and ligand endocytosis in regulating Notch signaling. Development 2005 132 1751 1762.
33. Nichols JT, Miyamoto A, Weinmaster G. Notch signaling - constantly on the move. Traffic 2007 8 959 969.
34. Parks AL, Klueg KM, Stout JR, Muskavitch MA. Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 2000 127 1373 1385.
35. Itoh M, Kim CH, Palardy G et al. Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta. Dev. Cell 2003 4 67 82.
36. Harrington LS, Sainson RC, Williams CK et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc. Res. 2008 75 144 154.
37. Sainson RC, Harris AL. Anti-Dll4 therapy: can we block tumor growth by increasing angiogenesis? Trends Mol. Med. 2007 13 389 395.
38. Yan M, Plowman GD. Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res. 2007 13 7243 7246.